Valbenazine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Trial Timeline
May 9, 2023 → Dec 27, 2024
NCT ID
NCT05859698About Valbenazine
Valbenazine is a approved stage product being developed by Neurocrine Biosciences for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT05859698. Target conditions include Schizophrenia, Schizoaffective Disorder, Bipolar Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07105111 | Approved | Recruiting |
| NCT05053321 | Phase 1 | Withdrawn |
| NCT06312189 | Phase 3 | Recruiting |
| NCT05859698 | Approved | Completed |
| NCT04400331 | Phase 3 | Active |
| NCT03444038 | Phase 2 | Completed |
| NCT02879578 | Phase 2 | Completed |
| NCT02736955 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia